Immunoglobulin G Therapy Dose Optimization

Last updated: November 12, 2024
Sponsor: Rutgers, The State University of New Jersey
Overall Status: Active - Recruiting

Phase

N/A

Condition

Obesity

Transplant Rejection

Diabetes Prevention

Treatment

Institutional standard intravenous immune globulin treatment

Clinical Study ID

NCT04818177
Pro20160000739
  • Ages 18-75
  • All Genders

Study Summary

The overall goal of this proposal is to investigate effects of obesity on pharmacokinetics of immunoglobulin G (IgG) and to develop strategies for optimization of dosing of IgG in obese patients. There is an ongoing debate regarding the most appropriate dosing of IgG formulations in obese patients. Obesity poses significant health risks; and evidence supporting dosing strategies of IgG in obese patients is inadequate. Some of the adverse reactions have been attributed to a relative overdosing in these patients, due to a limited distribution of IgG into fat tissue.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • aged 18 to 75 years

  • currently treated with IVIG

Exclusion

Exclusion Criteria:

  • liver impairment (elevations in liver enzymes of greater than 3 times the upperlimit of normal)

  • reduced renal function (CrCl < 50 mL/min)

  • Patients with a pacemaker or an automatic implantable cardioverter-defibrillator

Study Design

Total Participants: 40
Treatment Group(s): 1
Primary Treatment: Institutional standard intravenous immune globulin treatment
Phase:
Study Start date:
April 02, 2021
Estimated Completion Date:
December 01, 2025

Study Description

The estimated prevalence of overweight and obese individuals >20 years in the US is 154.7 million (nearly double since the early 1960s), and over 1.6 billion people are considered overweight or obese worldwide. Compounding the health risks associated with obesity is the insufficient data supporting dosing strategies for a variety of medication used to treat conditions encountered in obese patients. No consensus on the best dosing strategy for IgG in obese patients has been established. Total (TBW), ideal (IBW), and adjusted (AdjBW) body weight-based dosing are being utilized by different institutions. Thus, there is an urgent need to identify evidence supporting optimal dosing strategies for IgG.

It has been proposed that using TBW to dose IgG in obese patients may increase the risk of thrombosis owing to increased blood viscosity, activation of platelets, or vasospasm; and the increase in blood viscosity has been reported as IgG dose dependent. The use of using IBW or AdjBW has been advocated to reduce the side effect and drug expenditures. It is currently unknown what the clinical impact is of using measures of body weight other than TBW to calculate IgG doses, and the effect of obesity on IgG pharmacokinetics has not been experimentally evaluated.

Connect with a study center

  • Robert Wood Johnson University Hospital Somerset

    Somerville, New Jersey 08876
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.